Predictors of Clinical Stability and Mortality in COPD: A Longitudinal Study.

IF 2.7 3区 医学 Q2 RESPIRATORY SYSTEM
Wesley Teck Wee Loo, Si Yuan Chew, Jessica Han Ying Tan, Rui Ya Soh, Mariko Siyue Koh, Therese S Lapperre, Pei Yee Tiew
{"title":"Predictors of Clinical Stability and Mortality in COPD: A Longitudinal Study.","authors":"Wesley Teck Wee Loo, Si Yuan Chew, Jessica Han Ying Tan, Rui Ya Soh, Mariko Siyue Koh, Therese S Lapperre, Pei Yee Tiew","doi":"10.2147/COPD.S531435","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is no consensus on the definition of clinical stability in chronic obstructive pulmonary disease (COPD), and it is less frequently used as a treatment target compared to severe asthma. The factors that determine clinical stability and their effects on mortality are less well-studied in patients with COPD.</p><p><strong>Methods: </strong>To address this gap, we conducted a prospective longitudinal cohort study to identify predictors of two-year clinical stability, defined as no exacerbations and stable symptoms (<2 point change in CAT score from baseline), and the impact of comorbid cardiovascular disease (CVD) on clinical stability and mortality in COPD patients.</p><p><strong>Results: </strong>A total of 463 patients (mean age 71 ± 9 years) were enrolled in this study. The cohort was predominantly Chinese (81.7%) and 45.6% of participants were current smokers. The majority (55.7%) had a history of CVD. Approximately 36% of the cohort achieved clinical stability at one year, and one-third achieved stability at two years. Predictors of 2-year clinical stability included higher body mass index (BMI) (p<0.001), higher post-bronchodilator FEV1/FVC ratio (p=0.0132), fewer baseline exacerbations (p=0.007), absence of bronchiectasis (p=0.045), preserved hemoglobin levels (p=0.019), and successful smoking cessation (p=0.039). Notably, while 2-year clinical stability did not predict subsequent mortality, the presence of CVD was a significant predictor of 5-years mortality (HR 1.48, 95% CI 0.99-2.22; p=0.05).</p><p><strong>Conclusion: </strong>Our study identified several predictors of 2-year clinical stability in patients with COPD. However, clinical stability at 2 years did not predict subsequent mortality. These findings suggest that clinical stability and mortality are distinct outcomes that are driven by different sets of predictive variables. This underscores the need for a comprehensive approach to COPD management that not only addresses exacerbations and symptoms, but also considers a broader range of factors influencing survival, particularly the management of comorbidities such as cardiovascular disease.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2311-2324"},"PeriodicalIF":2.7000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12248741/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chronic Obstructive Pulmonary Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/COPD.S531435","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: There is no consensus on the definition of clinical stability in chronic obstructive pulmonary disease (COPD), and it is less frequently used as a treatment target compared to severe asthma. The factors that determine clinical stability and their effects on mortality are less well-studied in patients with COPD.

Methods: To address this gap, we conducted a prospective longitudinal cohort study to identify predictors of two-year clinical stability, defined as no exacerbations and stable symptoms (<2 point change in CAT score from baseline), and the impact of comorbid cardiovascular disease (CVD) on clinical stability and mortality in COPD patients.

Results: A total of 463 patients (mean age 71 ± 9 years) were enrolled in this study. The cohort was predominantly Chinese (81.7%) and 45.6% of participants were current smokers. The majority (55.7%) had a history of CVD. Approximately 36% of the cohort achieved clinical stability at one year, and one-third achieved stability at two years. Predictors of 2-year clinical stability included higher body mass index (BMI) (p<0.001), higher post-bronchodilator FEV1/FVC ratio (p=0.0132), fewer baseline exacerbations (p=0.007), absence of bronchiectasis (p=0.045), preserved hemoglobin levels (p=0.019), and successful smoking cessation (p=0.039). Notably, while 2-year clinical stability did not predict subsequent mortality, the presence of CVD was a significant predictor of 5-years mortality (HR 1.48, 95% CI 0.99-2.22; p=0.05).

Conclusion: Our study identified several predictors of 2-year clinical stability in patients with COPD. However, clinical stability at 2 years did not predict subsequent mortality. These findings suggest that clinical stability and mortality are distinct outcomes that are driven by different sets of predictive variables. This underscores the need for a comprehensive approach to COPD management that not only addresses exacerbations and symptoms, but also considers a broader range of factors influencing survival, particularly the management of comorbidities such as cardiovascular disease.

慢性阻塞性肺病临床稳定性和死亡率的预测因素:一项纵向研究。
背景:慢性阻塞性肺疾病(COPD)临床稳定性的定义尚未达成共识,与严重哮喘相比,它较少被用作治疗靶点。在慢性阻塞性肺病患者中,决定临床稳定性及其对死亡率影响的因素研究较少。方法:为了解决这一差距,我们进行了一项前瞻性纵向队列研究,以确定两年临床稳定性的预测因素,定义为无恶化和症状稳定(结果:共有463例患者(平均年龄71±9岁)参加了这项研究。该队列主要是中国人(81.7%),45.6%的参与者目前是吸烟者。大多数(55.7%)有心血管疾病史。大约36%的队列在一年内达到临床稳定,三分之一在两年内达到稳定。2年临床稳定性的预测因素包括较高的身体质量指数(BMI)(结论:我们的研究确定了COPD患者2年临床稳定性的几个预测因素。然而,2年的临床稳定性并不能预测随后的死亡率。这些发现表明,临床稳定性和死亡率是不同的结果,由不同的预测变量集驱动。这强调需要一种综合的方法来管理COPD,不仅要解决恶化和症状,还要考虑影响生存的更广泛的因素,特别是心血管疾病等合并症的管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.80
自引率
10.70%
发文量
372
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus will be given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is directed at specialists and healthcare professionals
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信